Sanofi sees midphase success in multiple sclerosis decades after safety concerns scuttled peers

Sanofi has laid down a marker in the race to revitalize an approach to treating autoimmune diseases. More than 20 years after a pre-merger Biogen and Idec independently raised safety concerns about the mechanism, the French drugmaker has presented phase 2 data that suggest its second-generation drug candidate may be safe and effective in multiple sclerosis.